Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sinopharm Group Co ( (HK:1099) ) has shared an update.
Sinopharm Group Co. Ltd. has announced its annual general meeting for 2024, scheduled for June 12, 2025, in Shanghai, China. Key agenda items include the approval of financial statements, profit distribution, director and supervisor remuneration, auditor appointments, and the delegation of guarantee provisions for subsidiaries. The meeting will also consider the appointment of new directors and the issuance of new shares, reflecting the company’s strategic focus on strengthening its governance and financial structure.
The most recent analyst rating on (HK:1099) stock is a Buy with a HK$29.30 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.
More about Sinopharm Group Co
Sinopharm Group Co. Ltd. is a joint stock limited company incorporated in the People’s Republic of China, operating in the healthcare industry. It is known for its pharmaceutical distribution and retail services, medical device manufacturing, and healthcare consulting, with a significant market presence in Hong Kong and mainland China.
Average Trading Volume: 7,707,441
Technical Sentiment Signal: Sell
Current Market Cap: HK$57.82B
See more data about 1099 stock on TipRanks’ Stock Analysis page.